Search

Displaying results 2821 - 2830 of 3917 in total
  1. Drug

    Saruparib

    go.drugbank.com/drugs/DB18982
    Investigational

    investigation in clinical trial NCT06380751 (Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in Hr-positive, Her2-negative (IHC 0, 1+, 2+/ ISH Non-amplified

  2. Drug

    Sirpiglenastat

    go.drugbank.com/drugs/DB17536
    Investigational

    Sirpiglenastat, also known as DRP-104, is a prodrug of [6-diazo-5-oxo-L-norleucine] (DON), which is a broad-acting glutamine antagonist.

  3. Drug

    Amylopectin

    go.drugbank.com/drugs/DB14927
    Experimental

    Amylopectin is under investigation in clinical trial NCT01708694 (Role of Slowly Digesible Starch on Diabetes Risk Factors).

  4. Drug

    Cafedrine

    go.drugbank.com/drugs/DB12926
    Investigational

    Cafedrine is under investigation in clinical trial NCT01311414 (Effect of Cafedrine/Theodrenaline and Urapidil on Cerebral Oxygenation).

  5. Drug

    Theodrenaline

    go.drugbank.com/drugs/DB12927
    Investigational

    Theodrenaline is under investigation in clinical trial NCT01311414 (Effect of Cafedrine/Theodrenaline and Urapidil on Cerebral Oxygenation).

  6. Drug

    Bebtelovimab

    go.drugbank.com/drugs/DB16755
    ApprovedWithdrawn

    [L40328] Bebtelovimab was issued an emergency use authorization (EUA) by the FDA on February 11, 2022, for the treatment of mild-to-moderate COVID-19 in select patients. … [L43827] On November 30, 2022, the EUA for bebtelovimab was officially withdrawn due to a lack of efficacy against Omicron subvariants, therefore bebtelovimab is no longer authorized for emergency use

  7. Drug

    Abrocitinib

    go.drugbank.com/drugs/DB14973
    ApprovedInvestigational

    [A244549] Abrocitinib was approved by the European Commission on December 10, 2021, for the treatment of moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy. … [L39784] On January 14, 2022, the FDA approved abrocitinib for the treatment of refractory, moderate-to-severe AD in adults whose disease is not adequately controlled with other systemic drug products,

  8. Drug

    Quazepam

    go.drugbank.com/drugs/DB01589
    ApprovedIllicit

    Quazepam is a trifluoroethyl benzodiazepine derivative. It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia. It appears to be unique amongst other benzodiazepine derivatives in its relatively h...

  9. Drug

    Phenylpropanolamine

    go.drugbank.com/drugs/DB00397
    ApprovedVet approvedWithdrawn

    Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from th...

  10. Drug

    Konjac mannan

    go.drugbank.com/drugs/DB14963
    Investigational

    Konjac mannan is under investigation in clinical trial NCT01709955 (The Effects of Glucomannan on Weight Loss).